Recent

12 April 2019

Fidia Pharma USA Inc Announces Expansion into the Dietary Supplement Market with Launch of CartiJoint™ FORTE

CartiJoint™ FORTE is the First Product in Fidia’s New Dietary Supplement Portfolio; Uniquely formulated with bioactive Bio-Curcumin Curcugreen™

12 March 2019

Fidia Pharma USA Inc Announces Expansion into Regenerative Medicine Markets with Launch of NuDYN™

Florham Park, NJ, March 12, 2019 – NuDYN™ is the First Product in Fidia’s New Orthobiologics Portfolio; A Novel Acellular Amnion-Derived Injectable Allograft

18 March 2018

Italian pharmaceutical R&D excellence at the 33rd Congress of the European Association of Urology

Copenhagen, March 18, 2018 – Fidia farmaceutici today announced the positive results from a phase II trial evaluating efficacy and tolerability of Oncofid®P-B, an innovative Paclitaxel-Hyaluronan Bioconjugate targeted to cancer cells, in patients with primary or recurrent Ta G1-G2 papillary bladder cancer.

Our Four Leading Principles:

Innovation

Quality

Internationalization

Competitiveness

Have Knee Pain?

Diagnosed with OSTEOARTHRITIS (OA) of the knee?

You may be eligible to participate in a clinical trial